FRED HUTCHINSON CANCER CENTER
🇺🇸United States
Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT06484595
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
EQQUAL-NM for the Promotion of Smoking Cessation in Sexual and Gender Minority Young Adults in New Mexico
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT06386432
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Evaluating the Impact of Centralized Interventions on Lung Cancer Screening Adherence in Community Settings, ACCELL Trial
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 6772
- Registration Number
- NCT06324110
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- Biological: Anti-STEAP1 CAR T-cellsProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: EnzalutamideDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06236139
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Expanding Clinical Trial Awareness Among Black Communities Through Digital Engagement
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 109
- Registration Number
- NCT06218615
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT06193070
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 776
- Registration Number
- NCT06145763
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Phase 1
Not yet recruiting
- Conditions
- Interventions
- Drug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Bridge TherapyProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Multigated Acquisition ScanBiological: T-cell Receptor-engineered T-cellsProcedure: X-Ray Imaging
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06094842
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Phase 1
Recruiting
- Conditions
- Interventions
- Drug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyBiological: T-cell Receptor-engineered T-cells
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06043713
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06034470
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath